Drug Repurposing and Repositioning Workshop Summary (2014) / Chapter Skim
Currently Skimming:
Appendix B: Speaker Biographical Sketches
Appendix B: Speaker Biographical Sketches
Pages 73-88
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 73... ...
Mr. Bartek's professional experience also includes 20 years of federal executive branch and legislative branch service in defense, foreign policy, and intelligence, including 6 years on the policy staff of the House Armed Services Committee; 4 years at the State Department's Bureau of Politico-Military Affairs, including a year as a negotiator on the U.S.
|
From page 74... ...
. The Butte Lab has also been developing novel methods for comparing clinical data from electronic health record systems with gene expression data, as described in Science (2008)
|
From page 75... ...
-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules, which tests a new model for public– private partnership collaborations, including template agreements to shorten the time it takes to establish collaborations between an academic institution and a pharmaceutical company and move more rapidly into the actual research. The pilot involves eight pharmaceutical companies that made 58 assets available for repurposing by the broader research community.
|
From page 76... ...
He conducted research in the Howard Hughes Medical Institute at the University of California, San Francisco. He earned an M.D.
|
From page 77... ...
He is an internationally recognized expert in genomics and personalized medicine with more than 200 published papers and funding from the National Institutes of Health, the Department of Defense, the Defense Advanced Research Projects Agency, the Gates Foundation, and industry. In 1990 he joined the faculty of Harvard Medical School, where he was director of preventive cardiology at Beth Israel Hospital and led a laboratory in applied genetics of cardiovascular disease at Children's Hospital.
|
From page 78... ...
Subsequently, he pursued postdoctoral training in clinical cardiovascular medicine at Beth Israel Hospital and in molecular biology at Children's Hospital as a Bugher Foundation Fellow of the American Heart Association. Petra Kaufmann, M.D., M.Sc., is director of the Office of Clinical Research (OCR)
|
From page 79... ...
Prior to Theranostics, Dr. Lavezzari worked at Social Scientific Systems, where she provided scientific support to and managed multiple AIDS clinical trials group, laboratory science, laboratory technical, and specialty laboratory committees, subcommittees, and working groups.
|
From page 80... ...
His responsibilities include developing the Therapeutics for Rare and Neglected Disease Program and the Bridging Interventional Development Gaps Program (formerly the NIH-RAID Program)
|
From page 81... ...
At FDA, he oversees review of investigational and new drug applications, contributes to regulatory policy development, and conducts research that supports FDA's core public health mission. Aidan Power, M.B., B.Ch., M.Sc., M.R.C.Psych., has been vice president and head of PharmaTx Precision Medicine since January 2008.
|
From page 82... ...
Recently her work has focused on advising the Defense Advanced Research Projects Agency and the National Human Genome Research Institute. She is currently co-chair of the IP Committee of the Administrative Law Section of the American Bar Assocation.
|
From page 83... ...
cum laude from Harvard Law School. He sits on the Board of The Nature Conservancy in Massachusetts.
|
From page 84... ...
He was one of the first clinical neurologists to apply molecular genetic strategies to neurological diseases. His laboratory reported the chromosomal location for more than 15 diseases, including several muscular dystrophies and Lou Gehrig's disease.
|
From page 85... ...
Public Health Service (1990) and the American Diabetes Association's Outstanding Scientific Achievement Award ("Lilly Award")
|
From page 86... ...
Health Sciences Policy Board, the National Coalition for Health Professional Education in Genetics board, and the International Rare Disease Research Consortium Interim Executive Committee, and she is a member of the IOM Roundtable on Translating Genomic-Based Research for Health. She is on the editorial boards of several journals.
|
From page 87... ...
He has been engaged in research administration at the MRC head office since 1999, with previous roles including responsibility for the MRC's clinical trials portfolio and the MRC's Health Services and Public Health Research Board, before leading its translational research activities beginning in 2008.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.